脂肪酸结合蛋白4 (FABP4)在肾病中的作用

Eckardt, K.U.; Coresh, J.; Devuyst, O.; Johnson, R.J.; Köttgen, A.; Levey, A.S.; Levin, A. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet, 2013, 382(9887), 158-169.
[http://dx.doi.org/10.1016/S0140-6736(13)60439-0] [PMID: 23727165]

Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A.Y.; Yang, C.W. Chronic kidney disease: global dimension and perspectives. Lancet, 2013, 382(9888), 260-272.
[http://dx.doi.org/10.1016/S0140-6736(13)60687-X] [PMID: 23727169]

Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; Alvarado, M.; Anderson, H.R.; Anderson, L.M.; Andrews, K.G.; Atkinson, C.; Baddour, L.M.; Barker-Collo, S.; Bartels, D.H.; Bell, M.L.; Benjamin, E.J.; Bennett, D.; Bhalla, K.; Bikbov, B.; Bin Abdulhak, A.; Birbeck, G.; Blyth, F.; Bolliger, I.; Boufous, S.; Bucello, C.; Burch, M.; Burney, P.; Carapetis, J.; Chen, H.; Chou, D.; Chugh, S.S.; Coffeng, L.E.; Colan, S.D.; Colquhoun, S.; Colson, K.E.; Condon, J.; Connor, M.D.; Cooper, L.T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K.C.; Couser, W.; Cowie, B.C.; Criqui, M.H.; Cross, M.; Dabhadkar, K.C.; Dahodwala, N.; De Leo, D.; Degenhardt, L.; Delossantos, A.; Denenberg, J.; Des Jarlais, D.C.; Dharmaratne, S.D.; Dorsey, E.R.; Driscoll, T.; Duber, H.; Ebel, B.; Erwin, P.J.; Espindola, P.; Ezzati, M.; Feigin, V.; Flaxman, A.D.; Forouzanfar, M.H.; Fowkes, F.G.; Franklin, R.; Fransen, M.; Freeman, M.K.; Gabriel, S.E.; Gakidou, E.; Gaspari, F.; Gillum, R.F.; Gonzalez-Medina, D.; Halasa, Y.A.; Haring, D.; Harrison, J.E.; Havmoeller, R.; Hay, R.J.; Hoen, B.; Hotez, P.J.; Hoy, D.; Jacobsen, K.H.; James, S.L.; Jasrasaria, R.; Jayaraman, S.; Johns, N.; Karthikeyan, G.; Kassebaum, N.; Keren, A.; Khoo, J.P.; Knowlton, L.M.; Kobusingye, O.; Koranteng, A.; Krishnamurthi, R.; Lipnick, M.; Lipshultz, S.E.; Ohno, S.L.; Mabweijano, J.; MacIntyre, M.F.; Mallinger, L.; March, L.; Marks, G.B.; Marks, R.; Matsumori, A.; Matzopoulos, R.; Mayosi, B.M.; McAnulty, J.H.; McDermott, M.M.; McGrath, J.; Mensah, G.A.; Merriman, T.R.; Michaud, C.; Miller, M.; Miller, T.R.; Mock, C.; Mocumbi, A.O.; Mokdad, A.A.; Moran, A.; Mulholland, K.; Nair, M.N.; Naldi, L.; Narayan, K.M.; Nasseri, K.; Norman, P.; O’Donnell, M.; Omer, S.B.; Ortblad, K.; Osborne, R.; Ozgediz, D.; Pahari, B.; Pandian, J.D.; Rivero, A.P.; Padilla, R.P.; Perez-Ruiz, F.; Perico, N.; Phillips, D.; Pierce, K.; Pope, C.A., III; Porrini, E.; Pourmalek, F.; Raju, M.; Ranganathan, D.; Rehm, J.T.; Rein, D.B.; Remuzzi, G.; Rivara, F.P.; Roberts, T.; De León, F.R.; Rosenfeld, L.C.; Rushton, L.; Sacco, R.L.; Salomon, J.A.; Sampson, U.; Sanman, E.; Schwebel, D.C.; Segui-Gomez, M.; Shepard, D.S.; Singh, D.; Singleton, J.; Sliwa, K.; Smith, E.; Steer, A.; Taylor, J.A.; Thomas, B.; Tleyjeh, I.M.; Towbin, J.A.; Truelsen, T.; Undurraga, E.A.; Venketasubramanian, N.; Vijayakumar, L.; Vos, T.; Wagner, G.R.; Wang, M.; Wang, W.; Watt, K.; Weinstock, M.A.; Weintraub, R.; Wilkinson, J.D.; Woolf, A.D.; Wulf, S.; Yeh, P.H.; Yip, P.; Zabetian, A.; Zheng, Z.J.; Lopez, A.D.; Murray, C.J.; AlMazroa, M.A.; Memish, Z.A. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859), 2095-2128.
[http://dx.doi.org/10.1016/S0140-6736(12)61728-0] [PMID: 23245604]

Wahba, I.M.; Mak, R.H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2007, 2(3), 550-562.
[http://dx.doi.org/10.2215/CJN.04071206] [PMID: 17699463]

Gameiro, J.; Gonçalves, M.; Pereira, M.; Rodrigues, N.; Godinho, I.; Neves, M.; Gouveia, J.; Silva, Z.C.E.; Jorge, S.; Lopes, J.A. Obesity, acute kidney injury and mortality in patients with sepsis: a cohort analysis. Ren. Fail., 2018, 40(1), 120-126.
[http://dx.doi.org/10.1080/0886022X.2018.1430588] [PMID: 29388454]

Briffa, J.F.; McAinch, A.J.; Poronnik, P.; Hryciw, D.H. Adipokines as a link between obesity and chronic kidney disease. Am. J. Physiol. Renal Physiol., 2013, 305(12), F1629-F1636.
[http://dx.doi.org/10.1152/ajprenal.00263.2013] [PMID: 24107418]

Yao, F.; Li, Z.; Ehara, T.; Yang, L.; Wang, D.; Feng, L.; Zhang, Y.; Wang, K.; Shi, Y.; Duan, H.; Zhang, L. Fatty Acid-Binding Protein 4 mediates apoptosis via endoplasmic reticulum stress in mesangial cells of diabetic nephropathy. Mol. Cell. Endocrinol., 2015, 411, 232-242.
[http://dx.doi.org/10.1016/j.mce.2015.05.003] [PMID: 25958041]

Shi, M.; Huang, R.; Guo, F.; Li, L.; Feng, Y.; Wei, Z.; Zhou, L.; Ma, L.; Fu, P. Pharmacological inhibition of fatty acid-binding protein 4 (fabp4) protects against renal ischemia-reperfusion injury. RSC Advances, 2018, 8, 15207-15214.
[http://dx.doi.org/10.1039/C8RA00122G]

Huang, R.; Shi, M.; Guo, F.; Feng, Y.; Feng, Y.; Liu, J.; Li, L.; Liang, Y.; Xiang, J.; Lei, S.; Ma, L.; Fu, P. Pharmacological inhibition of fatty acid-binding protein 4 (fabp4) protects against rhabdomyolysis-induced acute kidney injury. Front. Pharmacol., 2018, 9, 917.
[http://dx.doi.org/10.3389/fphar.2018.00917] [PMID: 30135658]

Furuhashi, M.; Tuncman, G.; Görgün, C.Z.; Makowski, L.; Atsumi, G.; Vaillancourt, E.; Kono, K.; Babaev, V.R.; Fazio, S.; Linton, M.F.; Sulsky, R.; Robl, J.A.; Parker, R.A.; Hotamisligil, G.S. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature, 2007, 447(7147), 959-965.
[http://dx.doi.org/10.1038/nature05844] [PMID: 17554340]

Furuhashi, M.; Hotamisligil, G.S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov., 2008, 7(6), 489-503.
[http://dx.doi.org/10.1038/nrd2589] [PMID: 18511927]

Spiegelman, B.M.; Frank, M.; Green, H. Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J. Biol. Chem., 1983, 258(16), 10083-10089.
[PMID: 6411703]

Hunt, C.R.; Ro, J.H.; Dobson, D.E.; Min, H.Y.; Spiegelman, B.M. Adipocyte P2 gene: developmental expression and homology of 5′-flanking sequences among fat cell-specific genes. Proc. Natl. Acad. Sci. USA, 1986, 83(11), 3786-3790.
[http://dx.doi.org/10.1073/pnas.83.11.3786] [PMID: 3520554]

Hertzel, A.V.; Bernlohr, D.A. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol. Metab., 2000, 11(5), 175-180.
[http://dx.doi.org/10.1016/S1043-2760(00)00257-5] [PMID: 10856918]

Melki, S.A.; Abumrad, N.A. Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation. J. Lipid Res., 1993, 34(9), 1527-1534.
[PMID: 7693843]

Distel, R.J.; Robinson, G.S.; Spiegelman, B.M. Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms. J. Biol. Chem., 1992, 267(9), 5937-5941.
[PMID: 1372897]

Makowski, L.; Boord, J.B.; Maeda, K.; Babaev, V.R.; Uysal, K.T.; Morgan, M.A.; Parker, R.A.; Suttles, J.; Fazio, S.; Hotamisligil, G.S.; Linton, M.F. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med., 2001, 7(6), 699-705.
[http://dx.doi.org/10.1038/89076] [PMID: 11385507]

Furuhashi, M.; Saitoh, S.; Shimamoto, K.; Miura, T. Fatty acid-binding protein 4 (fabp4): Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin. Med. Insights Cardiol., 2015, 8(Suppl. 3), 23-33.
[http://dx.doi.org/10.4137/CMC.S17067] [PMID: 25674026]

Pelton, P.D.; Zhou, L.; Demarest, K.T.; Burris, T.P. PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem. Biophys. Res. Commun., 1999, 261(2), 456-458.
[http://dx.doi.org/10.1006/bbrc.1999.1071] [PMID: 10425206]

Fu, Y.; Luo, N.; Lopes-Virella, M.F. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J. Lipid Res., 2000, 41(12), 2017-2023.
[PMID: 11108735]

Fu, Y.; Luo, N.; Lopes-Virella, M.F.; Garvey, W.T. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis, 2002, 165(2), 259-269.
[http://dx.doi.org/10.1016/S0021-9150(02)00305-2] [PMID: 12417276]

Kazemi, M.R.; McDonald, C.M.; Shigenaga, J.K.; Grunfeld, C.; Feingold, K.R. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler. Thromb. Vasc. Biol., 2005, 25(6), 1220-1224.
[http://dx.doi.org/10.1161/01.ATV.0000159163.52632.1b] [PMID: 15705927]

Wang, X.Q.; Yang, K.; He, Y.S.; Lu, L.; Shen, W.F. Receptor mediated elevation in FABP4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in THP-1 macrophages. Lipids, 2011, 46(6), 479-486.
[http://dx.doi.org/10.1007/s11745-011-3542-4] [PMID: 21336983]

Makowski, L.; Brittingham, K.C.; Reynolds, J.M.; Suttles, J.; Hotamisligil, G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem., 2005, 280(13), 12888-12895.
[http://dx.doi.org/10.1074/jbc.M413788200] [PMID: 15684432]

Diakov, T.T.; Kane, P.M. Regulation of vacuolar proton-translocating ATPase activity and assembly by extracellular pH. J. Biol. Chem., 2010, 285(31), 23771-23778.
[http://dx.doi.org/10.1074/jbc.M110.110122] [PMID: 20511227]

Shum, B.O.; Mackay, C.R.; Gorgun, C.Z.; Frost, M.J.; Kumar, R.K.; Hotamisligil, G.S.; Rolph, M.S. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J. Clin. Invest., 2006, 116(8), 2183-2192.
[http://dx.doi.org/10.1172/JCI24767] [PMID: 16841093]

Elmasri, H.; Karaaslan, C.; Teper, Y.; Ghelfi, E.; Weng, M.; Ince, T.A.; Kozakewich, H.; Bischoff, J.; Cataltepe, S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J., 2009, 23(11), 3865-3873.
[http://dx.doi.org/10.1096/fj.09-134882] [PMID: 19625659]

Rodríguez-Calvo, R.; Girona, J.; Alegret, J.M.; Bosquet, A.; Ibarretxe, D.; Masana, L. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J. Endocrinol., 2017, 233(3), R173-R184.
[http://dx.doi.org/10.1530/JOE-17-0031] [PMID: 28420707]

Gray, S.; Kim, J.K. New insights into insulin resistance in the diabetic heart. Trends Endocrinol. Metab., 2011, 22(10), 394-403.
[http://dx.doi.org/10.1016/j.tem.2011.05.001] [PMID: 21680199]

Xu, A.; Wang, Y.; Xu, J.Y.; Stejskal, D.; Tam, S.; Zhang, J.; Wat, N.M.; Wong, W.K.; Lam, K.S. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem., 2006, 52(3), 405-413.
[http://dx.doi.org/10.1373/clinchem.2005.062463] [PMID: 16423904]

Kralisch, S.; Fasshauer, M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia, 2013, 56(1), 10-21.
[http://dx.doi.org/10.1007/s00125-012-2737-4] [PMID: 23052058]

Cabré, A.; Lázaro, I.; Girona, J.; Manzanares, J.M.; Marimón, F.; Plana, N.; Heras, M.; Masana, L. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin. Chem., 2008, 54(1), 181-187.
[http://dx.doi.org/10.1373/clinchem.2007.094672] [PMID: 18024526]

Sommer, G.; Ziegelmeier, M.; Bachmann, A.; Kralisch, S.; Lossner, U.; Kratzsch, J.; Blüher, M.; Stumvoll, M.; Fasshauer, M. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD). Clin. Endocrinol. (Oxf.), 2008, 69(6), 901-905.
[http://dx.doi.org/10.1111/j.1365-2265.2008.03277.x] [PMID: 18419784]

Ebert, T.; Hopf, L.M.; Wurst, U.; Bachmann, A.; Kralisch, S.; Lössner, U.; Platz, M.; Kratzsch, J.; Stolzenburg, J.U.; Dietel, A.; Grisk, O.; Beige, J.; Anders, M.; Bast, I.; Klöting, N.; Blüher, M.; Stumvoll, M.; Fasshauer, M. Circulating adipocyte fatty acid binding protein is increased in chronic and acute renal dysfunction. Nutr. Metab. Cardiovasc. Dis., 2014, 24(9), 1027-1034.
[http://dx.doi.org/10.1016/j.numecd.2014.03.006] [PMID: 24813306]

Iwamoto, M.; Miyoshi, T.; Doi, M.; Takeda, K.; Kajiya, M.; Nosaka, K.; Nakayama, R.; Hirohata, S.; Usui, S.; Kusachi, S.; Sakane, K.; Nakamura, K.; Ito, H. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovasc. Diabetol., 2012, 11, 26.
[http://dx.doi.org/10.1186/1475-2840-11-26] [PMID: 22433902]

Toruner, F.; Altinova, A.E.; Akturk, M.; Kaya, M.; Arslan, E.; Bukan, N.; Kan, E.; Yetkin, I.; Arslan, M. The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes. Diabetes Res. Clin. Pract., 2011, 91(2), 203-207.
[http://dx.doi.org/10.1016/j.diabres.2010.11.011] [PMID: 21176857]

Yeung, D.C.; Xu, A.; Tso, A.W.; Chow, W.S.; Wat, N.M.; Fong, C.H.; Tam, S.; Sham, P.C.; Lam, K.S. Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients. Diabetes Care, 2009, 32(1), 132-134.
[http://dx.doi.org/10.2337/dc08-1333] [PMID: 18931100]

Okazaki, Y.; Furuhashi, M.; Tanaka, M.; Mita, T.; Fuseya, T.; Ishimura, S.; Watanabe, Y.; Hoshina, K.; Akasaka, H.; Ohnishi, H.; Yoshida, H.; Saitoh, S.; Shimamoto, K.; Miura, T. Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction. PLoS One, 2014, 9(12)e115429
[http://dx.doi.org/10.1371/journal.pone.0115429] [PMID: 25506691]

Yeung, D.C.; Xu, A.; Cheung, C.W.; Wat, N.M.; Yau, M.H.; Fong, C.H.; Chau, M.T.; Lam, K.S. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2007, 27(8), 1796-1802.
[http://dx.doi.org/10.1161/ATVBAHA.107.146274] [PMID: 17510463]

Xu, A.; Tso, A.W.; Cheung, B.M.; Wang, Y.; Wat, N.M.; Fong, C.H.; Yeung, D.C.; Janus, E.D.; Sham, P.C.; Lam, K.S. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation, 2007, 115(12), 1537-1543.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.647503] [PMID: 17389279]

Tso, A.W.; Xu, A.; Sham, P.C.; Wat, N.M.; Wang, Y.; Fong, C.H.; Cheung, B.M.; Janus, E.D.; Lam, K.S. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care, 2007, 30(10), 2667-2672.
[http://dx.doi.org/10.2337/dc07-0413] [PMID: 17620449]

El Nahas, M. Cardio-Kidney-Damage: a unifying concept. Kidney Int., 2010, 78(1), 14-18.
[http://dx.doi.org/10.1038/ki.2010.123] [PMID: 20445499]

Furuhashi, M.; Ishimura, S.; Ota, H.; Hayashi, M.; Nishitani, T.; Tanaka, M.; Yoshida, H.; Shimamoto, K.; Hotamisligil, G.S.; Miura, T. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One, 2011, 6(11)e27356
[http://dx.doi.org/10.1371/journal.pone.0027356] [PMID: 22102888]

Chen, Y.C.; Hsu, B.G.; Lee, C.J.; Ho, C.C.; Ho, G.J.; Lee, M.C. Serum adipocyte fatty acid-binding protein level is associated with arterial stiffness quantified with cardio-ankle vascular index in kidney transplant patients. Clin. Exp. Nephrol., 2018, 22(1), 188-195.
[http://dx.doi.org/10.1007/s10157-017-1438-1] [PMID: 28660445]

Tanaka, M.; Furuhashi, M.; Okazaki, Y.; Mita, T.; Fuseya, T.; Ohno, K.; Ishimura, S.; Yoshida, H.; Miura, T. Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction. Nephron Clin. Pract., 2014, 128(3-4), 345-351.
[http://dx.doi.org/10.1159/000368412] [PMID: 25592475]

Matthys, E.; Patel, Y.; Kreisberg, J.; Stewart, J.H.; Venkatachalam, M. Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int., 1984, 26(2), 153-161.
[http://dx.doi.org/10.1038/ki.1984.149] [PMID: 6503134]

Zimmerman, A.W.; Veerkamp, J.H. Fatty-acid-binding proteins do not protect against induced cytotoxicity in a kidney cell model. Biochem. J., 2001, 360(Pt 1), 159-165.
[http://dx.doi.org/10.1042/bj3600159] [PMID: 11696003]

Soccio, R.E.; Chen, E.R.; Rajapurkar, S.R.; Safabakhsh, P.; Marinis, J.M.; Dispirito, J.R.; Emmett, M.J.; Briggs, E.R.; Fang, B.; Everett, L.J.; Lim, H.W.; Won, K.J.; Steger, D.J.; Wu, Y.; Civelek, M.; Voight, B.F.; Lazar, M.A. Genetic variation determines ppargamma function and anti-diabetic drug response in vivo. Cell, 2015, 162(1), 33-44.
[http://dx.doi.org/10.1016/j.cell.2015.06.025] [PMID: 26140591]

Buckingham, R.E.; Al-Barazanji, K.A.; Toseland, C.D.; Slaughter, M.; Connor, S.C.; West, A.; Bond, B.; Turner, N.C.; Clapham, J.C. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes, 1998, 47(8), 1326-1334.
[http://dx.doi.org/10.2337/diabetes.47.8.1326] [PMID: 9703335]

Yoshimoto, T.; Naruse, M.; Nishikawa, M.; Naruse, K.; Tanabe, A.; Seki, T.; Imaki, T.; Demura, R.; Aikawa, E.; Demura, H. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am. J. Physiol., 1997, 272(6 Pt 1), E989-E996.
[http://dx.doi.org/10.1152/ajpendo.1997.272.6.E989] [PMID: 9227442]

Guan, Y.; Zhang, Y.; Schneider, A.; Davis, L.; Breyer, R.M.; Breyer, M.D. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am. J. Physiol. Renal Physiol., 2001, 281(6), F1036-F1046.
[http://dx.doi.org/10.1152/ajprenal.0025.2001] [PMID: 11704554]

Adida, A.; Spener, F. Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor gamma agonists in cultured cell. Biochim. Biophys. Acta, 2006, 1761(2), 172-181.
[http://dx.doi.org/10.1016/j.bbalip.2006.02.006] [PMID: 16574478]

Ayers, S.D.; Nedrow, K.L.; Gillilan, R.E.; Noy, N. Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. Biochemistry, 2007, 46(23), 6744-6752.
[http://dx.doi.org/10.1021/bi700047a] [PMID: 17516629]

Gillilan, R.E.; Ayers, S.D.; Noy, N. Structural basis for activation of fatty acid-binding protein 4. J. Mol. Biol., 2007, 372(5), 1246-1260.
[http://dx.doi.org/10.1016/j.jmb.2007.07.040] [PMID: 17761196]

Floresta, G.; Pistarà, V.; Amata, E.; Dichiara, M.; Marrazzo, A.; Prezzavento, O.; Rescifina, A. Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review. Eur. J. Med. Chem., 2017, 138, 854-873.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.022] [PMID: 28738306]

Hornigold, N.; Johnson, T.S.; Huang, L.; Haylor, J.L.; Griffin, M.; Mooney, A. Inhibition of collagen I accumulation reduces glomerulosclerosis by a Hic-5-dependent mechanism in experimental diabetic nephropathy. Lab. Invest., 2013, 93(5), 553-565.
[http://dx.doi.org/10.1038/labinvest.2013.42] [PMID: 23508044]

Xu, H.; Hertzel, A.V.; Steen, K.A.; Wang, Q.; Suttles, J.; Bernlohr, D.A. Uncoupling lipid metabolism from inflammation through fatty acid binding protein-dependent expression of UCP2. Mol. Cell. Biol., 2015, 35(6), 1055-1065.
[http://dx.doi.org/10.1128/MCB.01122-14] [PMID: 25582199]

Zarjou, A.; Agarwal, A. Sepsis and acute kidney injury. J. Am. Soc. Nephrol., 2011, 22(6), 999-1006.
[http://dx.doi.org/10.1681/ASN.2010050484] [PMID: 21566052]

Akchurin, O.M.; Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif., 2015, 39(1-3), 84-92.
[http://dx.doi.org/10.1159/000368940] [PMID: 25662331]